文献速递角膜与眼表疾病

评估诊疗一体化技术预测角膜交联治疗圆锥角膜效果的随机临床试验

Assessment of the Predictive Ability of Theranostics for Corneal Cross-linking in Treating Keratoconus: A Randomized Clinical Trial.
PubMed 文献 · Ophthalmology · 2024-06-20

这项前瞻性随机多中心设盲临床试验纳入50例进展性圆锥角膜患者,分层接受上皮去除或上皮保留方案的交联治疗,使用带诊疗一体化软件的紫外线A医疗设备。结果显示,诊疗一体化影像生物标志物预测1年最大角膜曲率平坦化超过0.1屈光度的准确度为91%、精确度为95%,最大角膜曲率中位数平坦化-1.3屈光度,裸眼和矫正远视力均改善,角膜内皮细胞密度和中央角膜厚度无显著变化。

要点

  • 诊疗一体化影像生物标志物预测1年最大角膜曲率平坦化超过0.1屈光度的准确度为91%,精确度为95%。
  • 交联后最大角膜曲率中位数平坦化-1.3屈光度(四分位距-2.11至-0.49,P<0.001)。
  • 裸眼和矫正远视力中位数均改善-0.1 logMAR,角膜内皮细胞密度和中央角膜厚度无显著变化。

核心结论

  • 研究证明将诊疗一体化整合到紫外线A医疗设备中,可对上皮去除和上皮保留交联方案治疗圆锥角膜进行精确且可预测的评估。
  • 角膜中核黄素浓度及其紫外线A光介导的光活化是决定交联疗效的主要因素。

研究设计与样本

  • 前瞻性、随机、多中心、设盲临床试验(ClinicalTrials.gov标识NCT05457647),纳入50例进展性圆锥角膜患者。

主要发现

  • 诊疗一体化影像生物标志物预测1年最大角膜曲率平坦化超过0.1屈光度的准确度为91%,精确度为95%。
  • 最大角膜曲率中位数平坦化-1.3屈光度(四分位距-2.11至-0.49,P<0.001)。
  • 裸眼远视力中位数改善-0.1 logMAR(四分位距-0.3至0.0,P<0.001),矫正远视力中位数改善-0.1 logMAR(四分位距-0.2至0.0,P<0.001)。
  • 术后1年角膜内皮细胞密度(P=0.33)和中央角膜厚度(P=0.07)无显著变化。

关键数值与推荐

  • 上皮去除方案25眼使用0.22%核黄素制剂点眼15分钟,上皮保留方案25眼使用0.22%核黄素制剂点眼20分钟。
  • 所有眼接受9分钟紫外线A照射,辐照度为10 mW/cm²。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To validate the ability of theranostic imaging biomarkers in assessing corneal cross-linking (CXL) efficacy in flattening the maximum keratometry (Kmax) index. DESIGN: Prospective, randomized, multicenter, masked clinical trial (ClinicalTrails.gov identifier, NCT05457647). PARTICIPANTS: Fifty patients with progressive keratoconus. INTERVENTION: Participants were stratified to undergo epithelium-off (25 eyes) and epithelium-on (25 eyes) CXL protocols using an ultraviolet A (UV-A) medical device with theranostic software. The device controlled UV-A light both for performing CXL and assessing the corneal riboflavin concentration (riboflavin score) and treatment effect (theranostic score). A 0.22% riboflavin formulation was applied onto the cornea for 15 minutes and 20 minutes in epithelium-off and epithelium-on protocols, respectively. All eyes underwent 9 minutes of UV-A irradiance at 10 mW/cm2. MAIN OUTCOME MEASURES: The primary outcome measure was validation of the combined use of theranostic imaging biomarkers through measurement of their accuracy (proportion of correctly classified eyes) and precision (positive predictive value) to classify eyes correctly and predict a Kmax flattening at 1 year after CXL. Other outcome measures included change in Kmax, endothelial cell density, uncorrected and corrected distance visual acuity, manifest spherical equivalent refraction and central corneal thickness 1 year after CXL. RESULTS: Accuracy and precision of the theranostic imaging biomarkers in predicting eyes that had >0.1 diopter (D) of Kmax flattening at 1 year were 91% and 95%, respectively. The Kmax value significantly flattened by a median of -1.3 D (IQR, -2.11 to -0.49 D; P < 0.001); both the uncorrected and corrected distance visual acuity improved by a median of -0.1 logarithm of the minimum angle of resolution (logMAR; IQR, -0.3 to 0.0 logMAR [P < 0.001] and -0.2 to 0.0 logMAR [P < 0.001], respectively). No significant changes in endothelial cell density (P = 0.33) or central corneal thickness (P = 0.07) were noted 1 year after surgery. CONCLUSIONS: The study demonstrated the efficacy of integrating theranostics in a UV-A medical device for the precise and predictive treatment of keratoconus with epithelium-off and epithelium-on CXL protocols. Concentration of riboflavin and its UV-A light mediated photoactivation in the cornea are the primary factors determining CXL efficacy. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Roszkowska AM, Scorcia V, Mencucci R, et al. Assessment of the Predictive Ability of Theranostics for Corneal Cross-linking in Treating Keratoconus: A Randomized Clinical Trial. Ophthalmology. 2024. PMID: 38908553. doi:10.1016/j.ophtha.2024.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。